{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:52:26Z","timestamp":1783612346634,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphoplasmapheresis (LPE) is a new therapy developed on the basis of traditional plasma exchange (PE) in combination with leukapheresis. Currently, it remains unclear whether PE and LPE show differences in efficacy for severe MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 198 MG patients, 75 in the PE group and 123 in the LPE group, and the patients\u2019 Myasthenia Gravis Foundation of America (MGFA) Clinical Classification was Class IV. The treatment outcome was the change in Quantitative Myasthenia Gravis Score (QMGS) from baseline to the end of treatment. Propensity score matching (PSM) was applied for the balance of confounders between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study cohort, the safety profile of LPE and PE was good and no serious adverse events were observed. Based on PSM, 62 patients treated with LPE and 62 patients treated with PE were entered into a comparative efficacy analysis. In the PE group, patients underwent a total of 232 replacements, with a mean of 3.74. PE significantly improved the patients\u2019 QMGS performance, with the mean QMGS decreasing from 22.98\u2009\u00b1\u20094.03 points at baseline to 18.34\u2009\u00b1\u20095.03 points after treatment, a decrease of 4.68\u2009\u00b1\u20094.04 points (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). A decrease of \u22653 points in QMGS was considered a significant improvement, with a treatment response rate of 67.7% in the PE group. In the LPE group, patients received a total of 117 replacements, with a mean of 1.89. The patients\u2019 mean QMGS was 23.19\u2009\u00b1\u20094.11 points at baseline and was 16.94\u2009\u00b1\u20095.78 points after treatment, a decrease of 6.26\u2009\u00b1\u20094.39 points (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The improvement in QMGS was more significant in patients treated with LPE compared to the PE group (<jats:italic>p<\/jats:italic>\u2009=\u20090.039). The treatment response rate in the LPE group was 79%, which was not significantly different compared to the PE group (<jats:italic>p<\/jats:italic>\u2009=\u20090.16). The LEP group had a shorter mean length of stay compared to the PE group (10.86\u2009\u00b1\u20093.96 vs. 12.14\u2009\u00b1\u20094.14\u2009days), but the difference was not statistically significant (<jats:italic>p<\/jats:italic> =\u20090.13). During the 2-month follow-up period, LPE may be associated with better functional outcomes for patients, with lower QMG score and relapse rate. LPE and PE were both effective in reducing the levels of inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, and IL-6) and AChR-Ab. Compared to PE, LPE was superior in the reduction of AChR-Ab titer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In severe MG, LPE may be a more preferred treatment option than PE. It achieves treatment outcomes that are not inferior to or even better than PE with fewer replacements. This study provides further evidence to support the application of LPE as a new treatment option for MG.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1212868","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T10:27:16Z","timestamp":1687861636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Weiwei","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fneur.2020.00981","article-title":"From traditional to targeted immunotherapy in myasthenia gravis: prospects for research","volume":"11","author":"Mantegazza","year":"2020","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fimmu.2019.00324","article-title":"Application of plasma exchange in steroid-responsive encephalopathy","volume":"10","author":"Jiang","year":"2019","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e14092","DOI":"10.1111\/dth.14092","article-title":"Successful use of lymphoplasma exchange in a patient with acute generalized pustular psoriasis of von Zumbusch","volume":"33","author":"Zhang","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1111\/1346-8138.15598","article-title":"Striking case of febrile ulceronecrotic Mucha-Habermann disease responding to lymphoplasmapheresis and methotrexate","volume":"47","author":"Wang","year":"2020","journal-title":"J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14715\/cmb\/2017.63.10.17","article-title":"Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of Guillain-Barre syndrome","volume":"63","author":"Luo","year":"2017","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.21037\/apm-21-177","article-title":"The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"757841","DOI":"10.3389\/fimmu.2022.757841","article-title":"Lymphoplasma exchange improves myasthenia gravis exacerbations: a retrospective study in a Chinese center","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/16078454.2021.2015842","article-title":"Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1756285616637046","article-title":"Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration","volume":"9","author":"Schneider-Gold","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00415-006-0235-7","article-title":"Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial","volume":"254","author":"Trikha","year":"2007","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JND-150082","article-title":"Psychometric properties of the quantitative myasthenia gravis score and the myasthenia gravis composite scale","volume":"2","author":"Barnett","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13591","article-title":"An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients","volume":"1413","author":"Villegas","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.jaut.2019.102337","article-title":"Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers","volume":"106","author":"Lefeuvre","year":"2020","journal-title":"J Autoimmun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/jaut.2002.0618","article-title":"Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis","volume":"19","author":"Duan","year":"2002","journal-title":"J Autoimmun"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00415-011-6036-7","article-title":"Elevated serum level of interleukin-32\u03b1 in the patients with myasthenia gravis","volume":"258","author":"Na","year":"2011","journal-title":"J Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1212868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T10:27:55Z","timestamp":1687861675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1212868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":34,"alternative-id":["10.3389\/fneur.2023.1212868"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1212868","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"article-number":"1212868"}}